Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The companys major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Licensing Agreements 17
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 17
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 18
Equity Offering 19
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 19
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 20
Ironwood Pharma Completes Partial Exercise Of Underwriters Option For Public Offering Of Shares For US$146 Million 22
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 24
Debt Offering 26
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 26
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 27
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 28
Ironwood Pharmaceuticals Inc - Key Competitors 29
Ironwood Pharmaceuticals Inc - Key Employees 30
Ironwood Pharmaceuticals Inc - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 32
Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 34
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 37
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 42
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 44
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 46
Corporate Communications 50
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 50
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 51
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 52
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 53
Government and Public Interest 54
May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 54
Clinical Trials 56
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 56
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 58
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 59
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 61
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 63
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 64
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 65
Other Significant Developments 66
May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 66
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List Of Tables

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 17
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 18
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 19
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 20
Ironwood Pharma Completes Partial Exercise Of Underwriters Option For Public Offering Of Shares For US$146 Million 22
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 24
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 26
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 27
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 28
Ironwood Pharmaceuticals Inc, Key Competitors 29
Ironwood Pharmaceuticals Inc, Key Employees 30
Ironwood Pharmaceuticals Inc, Subsidiaries 31

List Of Figures

List of Figures
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The companys major products include Linzess (linaclotide), an oral capsule for the

USD 250 View Report

Ironwood Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Ironwood Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Ironwood Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Cannabics Pharmaceuticals Inc (CNBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available